GlycanAge (IgG Glycosylation Age)

GlycanAge is a commercial biological-age test built on IgG N-glycosylation patterns, the sugar structures attached to immunoglobulin G antibodies that shift in composition as the immune system ages, distinct from and complementary to DNA-methylation-based epigenetic clocks. The claim: the balance of specific glycan structures on IgG, particularly the ratio of galactosylated to non-galactosylated (agalactosylated) glycans, reflects immune inflammatory age and correlates with chronological age and health status more broadly than chronological age alone.

The core scientific literature underlying GlycanAge stems from population studies establishing that IgG glycosylation patterns change progressively and measurably across the human lifespan and correlate with markers of chronic low-grade inflammation, with an early large population study establishing the age-association across a substantial cohort of individuals with known genealogical and genetic data [1]. GlycanAge's own published science page cites validation across multiple population cohorts linking their glycan-based score with age and with several age-related conditions [2]. A subsequent industry-associated study, publicized in 2025, reported that therapeutic plasma exchange (a blood-filtering treatment) produced measurable reductions in glycan-based aging scores, positioned as further validating glycans as a modifiable aging biomarker, though this finding stems from an industry press release rather than a peer-reviewed publication with full methodological transparency available for independent scrutiny [3].

How to measure it: GlycanAge and academic glycomics labs analyze IgG N-glycans from a blood sample using ultra-performance liquid chromatography (UPLC) or mass spectrometry, quantifying the relative abundance of specific glycan structures such as galactosylation, sialylation, bisecting GlcNAc, and fucosylation, and combining them into a composite glycan age score [4].

How to intervene on it: no randomized controlled trial has established a specific intervention that reliably lowers GlycanAge with a corresponding health or mortality benefit; the commercial product markets lifestyle changes (diet, exercise, alcohol reduction) as glycan-improving based on general anti-inflammatory principles rather than glycan-specific trial evidence, and the plasma-exchange finding, while intriguing, is a single industry-reported result requiring independent replication before it can be considered established.

Critics note that unlike the Horvath or PhenoAge epigenetic clocks, GlycanAge lacks large, independent, peer-reviewed mortality-outcome validation of comparable scale; most published support comes from company-affiliated researchers or industry-funded studies [2][3], a gap flagged in independent aging-biomarker review coverage [5].

Bryan Johnson's Blueprint protocol includes glycan-based testing as one of many panel items, an n=1 self-report rather than validation data [6].

The plain takeaway: GlycanAge captures a biologically plausible and distinct dimension of immune aging through antibody sugar chemistry, but its evidence base is considerably thinner and more industry-associated than established epigenetic clocks, so it should be treated as an exploratory research tool rather than a validated clinical mortality predictor at this stage.